OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
BioMarin Pharmaceutical OCF Yield % Related Terms
BioMarin Pharmaceutical OCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:BM8 vs CYTK, ARWR, TECH: OCF Yield % Comparison
For the Biotechnology subindustry, BioMarin Pharmaceutical's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioMarin Pharmaceutical OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioMarin Pharmaceutical's OCF Yield % distribution charts can be found below:
* The bar in red indicates where BioMarin Pharmaceutical's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioMarin Pharmaceutical (HAM:BM8) has a OCF Yield % of 7.67 as of Jul. 05, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on BioMarin Pharmaceutical and its competitors. This is 824% above median its historical median of 0.83. According to the industry distribution chart, BioMarin Pharmaceutical ranks #83 out of 1410 companies in the Biotechnology industry, placing it in the top 5.9%.
Is BioMarin Pharmaceutical's OCF Yield % too high?
BioMarin Pharmaceutical's current OCF Yield % of 7.67 is 824% above median its 10-year median of 0.83. Based on the distribution chart, BioMarin Pharmaceutical ranks #83 out of 1410 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioMarin Pharmaceutical has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's OCF Yield % compare to CYTK and ARWR?
According to the Biotechnology industry distribution chart, BioMarin Pharmaceutical ranks #83 out of 1410 companies for OCF Yield %. This places BioMarin Pharmaceutical in the top 6% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on BioMarin Pharmaceutical and its competitors. BioMarin Pharmaceutical's current OCF Yield % is 7.67, which is 824% above median its own 10-year median of 0.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
BioMarin Pharmaceutical (HAM:BM8) has a current OCF Yield % of 7.67. The stock's GF Value™ is €77.35, compared to a current price of €52.04 — trading 32.7% below its estimated fair value. The current OCF Yield % is 7.67, which is 824% above median its 10-year median of 0.83. BioMarin Pharmaceutical's overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For BioMarin Pharmaceutical (HAM:BM8), the current OCF Yield % is 7.67 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioMarin Pharmaceutical (HAM:BM8) Overvalued in 2026?
Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued.
The current stock price of €52.04 is trading 32.7% below its estimated GF Value™ of €77.35.
Key valuation signals for HAM:BM8:
OCF Yield %: 7.67 (824% above median its 10-year median of 0.83)
GF Value™: €77.35 vs. price of €52.04 (32.7% below fair value)
No single metric tells the full story. See the HAM:BM8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
75GF Score
Get the complete analysis for HAM:BM8
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:BM8 has been successfully added to your 
